How does CLM's PS Ratio compare to its peers?

CLM is good value based on its Price-To-Sales Ratio (10.6x) compared to the peer average (11.8x).

How does CLM's PS Ratio compare vs other companies in the European Pharmaceuticals Industry?

CLM is expensive based on its Price-To-Sales Ratio (10.6x) compared to the European Pharmaceuticals industry average (3.1x).

What is CLM's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

Insufficient data to calculate CLM's Price-To-Sales Fair Ratio for valuation analysis.

What is the Fair Price of CLM when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Insufficient data to calculate CLM's fair value for valuation analysis.

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Target price is more than 20% higher than the current share price, but analysts are not within a statistically confident range of agreement.

Clearside Biomedical (BST:CLM) - Stock Price, News & Analysis

CLM Stock Overview

A biopharmaceutical company, focuses on the revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space. More details

CLM fundamental analysis
Snowflake Score
Valuation	1/6
Future Growth	2/6
Past Performance	0/6
Financial Health	1/6
Dividends	0/6

Rewards

Revenue is forecast to grow 64.87% per year

Risk Analysis

Shares are highly illiquid

Negative shareholders equity

Has less than 1 year of cash runway

Does not have a meaningful market cap (€77M)

+ 2 more risks

Clearside Biomedical, Inc. Competitors

Apontis Pharma

XTRA:APPH

€80.3m

Pierrel

DB:2FJ0

€92.8m

Cantourage Group

XTRA:HIGH

€55.6m

Redx Pharma

DB:0RX

€65.0m

Price History & Performance

Summary of all time highs, changes and price drops for Clearside Biomedical
Historical stock prices
Current Share Price	US$0.99
52 Week High	US$1.41
52 Week Low	US$0.90
Beta	2.33
11 Month Change	n/a
3 Month Change	n/a
1 Year Change	n/a
33 Year Change	-75.06%
5 Year Change	-19.51%
Change since IPO	-90.16%

Recent updates

Shareholder Returns

	CLM	DE Pharmaceuticals	DE Market
7D	n/a	-1.2%	-0.02%
1Y	n/a	-20.1%	8.2%

Return vs Industry: Insufficient data to determine how CLM performed against the German Pharmaceuticals industry.

Return vs Market: Insufficient data to determine how CLM performed against the German Market.

Price Volatility

Is CLM's price volatile compared to industry and market?
CLM volatility
CLM Average Weekly Movement	n/a
Pharmaceuticals Industry Average Movement	6.9%
Market Average Movement	4.8%
10% most volatile stocks in DE Market	10.9%
10% least volatile stocks in DE Market	2.4%

Stable Share Price: CLM's share price has been volatile over the past 3 months compared to the German market.

Volatility Over Time: Insufficient data to determine CLM's volatility change over the past year.

About the Company

Founded	Employees	CEO	Website
2011	30	George Lasezkay	clearsidebio.com

Clearside Biomedical, Inc., a biopharmaceutical company, focuses on the revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space. It offers XIPERE, a triamcinolone acetonide suprachoroidal injectable suspension for the treatment of uveitis macular edema. It also develops CLS-AX, an axitinib injectable suspension for suprachoroidal injection, which is in Phase IIb clinical trial to treat wet AMD.

Clearside Biomedical, Inc. Fundamentals Summary

How do Clearside Biomedical's earnings and revenue compare to its market cap?
CLM fundamental statistics
Market cap	€74.29m
Earnings (TTM)	-€30.61m
Revenue (TTM)	€7.40m

10.6x

P/S Ratio

-2.6x

P/E Ratio

Is CLM overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
CLM income statement (TTM)
Revenue	US$7.70m
Cost of Revenue	US$0
Gross Profit	US$7.70m
Other Expenses	US$39.58m
Earnings	-US$31.88m

Last Reported Earnings

Sep 30, 2024

Next Earnings Date

n/a

Earnings per share (EPS)	-0.42
Gross Margin	100.00%
Net Profit Margin	-413.84%
Debt/Equity Ratio	-141.4%

How did CLM perform over the long term?

See historical performance and comparison

CLM Stock Overview

Rewards

Risk Analysis

Clearside Biomedical, Inc. Competitors

XTRA:APPH

€80.3m

DB:2FJ0

€92.8m

XTRA:HIGH

€55.6m

DB:0RX

€65.0m

Price History & Performance

Recent News & Updates

Clearside Biomedical, Inc. Announces Board Changes

Clearside Biomedical, Inc. to Report Q3, 2024 Results on Nov 12, 2024

Clearside Biomedical, Inc. Announces Positive Topline Results from ODYSSEY Phase 2b Trial of Suprachoroidal CLS-AX in Wet AMD Achieving All Primary and Secondary Outcomes

Clearside Biomedical Announces Completion of Final Participant Visit in ODYSSEY Phase 2b Trial of CLS-AX in Wet AMD

Clearside Biomedical, Inc. to Report Q2, 2024 Results on Aug 12, 2024

Clearside Biomedical's Partner Arctic Vision Reports Positive Topline Results from Phase 3 Clinical Trial of Arcatus for Suprachoroidal Use in Uveitic Macular Edema Patients in China

Recent updates

Clearside Biomedical, Inc. Announces Board Changes

Clearside Biomedical, Inc. to Report Q3, 2024 Results on Nov 12, 2024

Clearside Biomedical, Inc. Announces Positive Topline Results from ODYSSEY Phase 2b Trial of Suprachoroidal CLS-AX in Wet AMD Achieving All Primary and Secondary Outcomes

Clearside Biomedical Announces Completion of Final Participant Visit in ODYSSEY Phase 2b Trial of CLS-AX in Wet AMD

Clearside Biomedical, Inc. to Report Q2, 2024 Results on Aug 12, 2024

Clearside Biomedical's Partner Arctic Vision Reports Positive Topline Results from Phase 3 Clinical Trial of Arcatus for Suprachoroidal Use in Uveitic Macular Edema Patients in China

Clearside Biomedical, Inc. Appoints Dr. Glenn Yiu to Its Scientific Advisory Board

First quarter 2024 earnings released: US$0.17 loss per share (vs US$0.15 loss in 1Q 2023)

Clearside Biomedical, Inc. to Report Q1, 2024 Results on May 09, 2024

Clearside Biomedical, Inc., Annual General Meeting, Jun 20, 2024

Insider recently bought €122k worth of stock

New minor risk - Market cap size

Clearside Biomedical, Inc Appoints Anthony S. Gibney to its Board of Directors

Clearside Biomedical Appoints Victor Chong, M.D., MBA as Chief Medical Officer

Clearside Biomedical, Inc. to Report Q4, 2023 Results on Mar 12, 2024

Clearside Biomedical, Inc. has filed a Follow-on Equity Offering in the amount of $15 million.

Clearside Biomedical, Inc. has filed a Follow-on Equity Offering in the amount of $15 million.

Clearside Biomedical, Inc. has filed a Follow-on Equity Offering.

Clearside Biomedical, Inc. Reports Significant Progress in ODYSSEY Phase 2b Trial of CLS-AX in Wet AMD

Third quarter 2023 earnings released: US$0.15 loss per share (vs US$0.13 loss in 3Q 2022)

New major risk - Negative shareholders equity

Clearside Biomedical, Inc. to Report Q3, 2023 Results on Nov 13, 2023

Clearside Biomedical Positive OASIS and Extension Study Data Presented at The Retina Society 56th Annual Scientific Meeting

Clearside Biomedical Positive OASIS and Extension Study Data Presented at The Retina Society 56th Annual Scientific Meeting

Clearside Biomedical Receives Non-Compliance Notice from Nasdaq

Clearside Biomedical, Inc. to Report Q2, 2023 Results on Aug 14, 2023

Clearside Biomedical Highlights Excellent Safety Profile of CLS-AX and Potential for Extended Duration of Effect in Data Presentation At the American Society of Retina Specialists 41st Annual Scientific Meeting

Clearside Biomedical Asia-Pacific Partner Arctic Vision Announces the Acceptance in Australia of Its New Drug Application for Suprachoroidal Use of Arcatus® for the Treatment of Uveitic Macular Edema

Clearside Biomedical, Inc. Opens Enrollment in Odyssey Phase 2B Clinical Trial of Cls-Ax (Axitinib Injectable Suspension) in Wet AMD

First quarter 2023 earnings released: US$0.15 loss per share (vs US$0.13 loss in 1Q 2022)

High number of new directors

Clearside Biomedical, Inc. Executive Changes, Effective February 17, 2023

Clearside Biomedical Announces Positive 6-Month Results from OASIS Extension Study with Suprachoroidal CLS-AX (axitinib injectable suspension) in Wet AMD

Clearside Biomedical, Inc. Announces Positive Results in Safety, Durability and Biologic Effect in Oasis Phase 1/2A Clinical Trial of Suprachoroidal CLS-AX (axitinib Injectable Suspension) in Wet AMD Patients

Clearside Biomedical, Inc. to Report Q3, 2022 Results on Nov 09, 2022

High number of new directors

Clearside Biomedical, Inc. to Report Q2, 2022 Results on Aug 09, 2022

Clearside Biomedical Completes Dosing in Oasis Phase 1/2A Clinical Trial of CLS-AX in Wet AMD Patients

Clearside Biomedical, Inc. Appoints Susan Coultas as Chief Clinical Officer

First quarter 2022 earnings released: US$0.13 loss per share (vs US$0.13 loss in 1Q 2021)

High number of new directors

Clearside Biomedical, Inc., Annual General Meeting, Jun 22, 2022

Bausch + Lomb and Clearside Biomedical, Inc. Announce the U.S. Commercial Launch of XIPERE® (Triamcinolone Acetonide Injectable Suspension) for Suprachoroidal Use for the Treatment of Macular Edema Associated with Uveitis

High number of new directors

Clearside Biomedical, Inc. Appoints Benjamin R. Yerxa to Its Board of Directors

Clearside Biomedical, Inc. to Report Q4, 2021 Results on Mar 10, 2022

Clearside Biomedical’s Suprachoroidal Injection Platform Featured at the Angiogenesis, Exudation, and Degeneration 2022 Virtual Conference

High number of new and inexperienced directors

Clearside Biomedical Announces Positive Safety Results from OASIS Phase 1/2a Clinical Trial of CLS-AX (axitinib injectable suspension) for the Treatment of Wet AMD

High number of new and inexperienced directors

High number of new and inexperienced directors

High number of new and inexperienced directors

Clearside Biomedical Announces Completion of Dosing in Cohort 2 of Phase 1/2a Clinical Trial of CLS-AX (axitinib injectable suspension) in Wet AMD Patients

High number of new and inexperienced directors

Second quarter 2021 earnings released: US$0.11 loss per share (vs US$0.13 loss in 2Q 2020)

Clearside Biomedical Announces Positive Safety Results from Cohort 1 of OASIS Phase 1/2a Clinical Trial of CLS-AX (axitinib injectable suspension) for the Treatment of Wet AMD

Bausch Health and Clearside Biomedical Announce U.S. FDA Filing Acceptance for XIPERE (Triamcinolone Acetonide Suprachoroidal Injectable Suspension)

First quarter 2021 earnings released: US$0.13 loss per share (vs US$0.065 loss in 1Q 2020)

Clearside Biomedical, Inc. Announces Resubmission of New Drug Application for XIPERE™ for Treatment of Macular Edema Associated with Uveitis